移植预处理方案、NPM1突变与可测量残留病对FLT3-ITD急性髓系白血病的影响
本文为血液与骨髓移植临床试验网络1506(MORPHO)随机试验的事后分析,该试验比较吉瑞替尼与安慰剂作为FLT3-ITD突变急性髓系白血病患者异基因造血干细胞移植后维持治疗的效果。分析聚焦预处理方案强度、可测量残留病(MRD)与诊断时NPM1共突变状态之间的交互作用。
要点
- 比较预处理前后FLT3-ITD MRD,清髓性预处理(MAC)与减低强度预处理(RIC)在清除或降低FLT3-ITD MRD方面无差异。
- 移植前FLT3-ITD MRD阴性的参与者中,接受MAC与RIC者的随访期间累积复发率无差异。
- NPM1共突变与移植后吉瑞替尼带来的最大无复发生存获益相关;在这些参与者中,RIC背景下移植后吉瑞替尼在预防复发方面似乎与MAC同样有效。
核心结论
- 研究结果表明,仅部分接受移植的FLT3-ITD急性髓系白血病患者可能从MAC中获益。
- 与移植前急性髓系白血病治疗类似,移植预处理方案的强度应根据疾病的分子特征进行调整。
研究设计与样本
- 本研究为血液与骨髓移植临床试验网络1506(MORPHO)随机试验的事后分析。
- 该试验比较吉瑞替尼与安慰剂作为移植后维持治疗,对象为接受异基因造血干细胞移植的FLT3-ITD突变急性髓系白血病患者。
- 分析聚焦预处理方案强度、可测量残留病(MRD)与诊断时报告的NPM1共突变状态之间的交互作用。
- 该试验在www.clinicaltrials.gov注册,注册号为NCT02997202。
主要发现
- 比较预处理前后FLT3-ITD MRD,MAC与RIC在清除或降低FLT3-ITD MRD方面无差异。
- 对于移植前FLT3-ITD MRD阴性的参与者,随访期间接受MAC与RIC者的累积复发率无差异。
- NPM1共突变与移植后吉瑞替尼带来的最大无复发生存获益相关;在这些参与者中,RIC背景下移植后吉瑞替尼在预防复发方面似乎与MAC同样有效。
- 仅在诊断时NPM1野生型且移植前FLT3-ITD MRD阳性的参与者中,MAC在预防复发方面似乎优于RIC。
关键数值与推荐
- 比较预处理前后FLT3-ITD MRD,MAC与RIC在清除或降低FLT3-ITD MRD方面无差异。
- 移植前FLT3-ITD MRD阴性的参与者中,MAC与RIC的累积复发率无差异。
- NPM1共突变与移植后吉瑞替尼的最大无复发生存获益相关;在该亚组中,RIC背景下移植后吉瑞替尼在预防复发方面似乎与MAC同样有效。
- 在诊断时NPM1野生型且移植前FLT3-ITD MRD阳性的参与者中,MAC在预防复发方面似乎优于RIC。
临床怎么用
- 研究结果表明,仅部分接受移植的FLT3-ITD急性髓系白血病患者可能从MAC中获益。
- 作者认为,与移植前急性髓系白血病治疗类似,移植预处理方案的强度应根据疾病的分子特征进行调整。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We conducted a post hoc analysis of data from Blood and Marrow Transplant Clinical Trials Network 1506 (MORPHO), a randomized trial of gilteritinib vs placebo as posttransplantation maintenance for patients with FLT3-ITD-mutated acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (HCT), focusing the interactions between conditioning regimen intensity, measurable residual disease (MRD), and NPM1 comutation status reported from diagnosis. Comparing FLT3-ITD MRD before and after conditioning, there was no difference between myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) in eradication or reduction of FLT3-ITD MRD. For participants who were FLT3-ITD MRD negative before HCT, there was no difference in the cumulative incidence of relapse during follow-up between those receiving MAC vs RIC. NPM1 comutation was associated with the largest magnitude of relapse-free survival benefit from post-HCT gilteritinib, and in these participants, post-HCT gilteritinib in the setting of RIC appeared to be as effective as MAC at preventing relapse. MAC appeared superior to RIC in preventing relapse only in participants who were NPM1 wild type at diagnosis and FLT3-ITD MRD positive before HCT. Our findings suggest that only a subset of patients with FLT3-ITD AML undergoing HCT may benefit from MAC and that, similar to AML therapy before HCT, the intensity of the HCT regimen should be adapted according to the molecular features of the disease. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
引用
- Levis MJ, Hamadani M, Logan BR, et al. Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia. Blood Adv. 2025. PMID: 40590852. doi:10.1182/bloodadvances.2025016306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。